p-Index From 2015 - 2020
0.408
P-Index
This Author published in this journals
All Journal JFIOnline
Kurniati, Tripeni
Indonesian Research Gateway

Published : 2 Documents
Articles

Found 2 Documents
Search

AMBARAN FUNGSI HATI PASIEN SKIZOFRENIA YANG MENGKONSUMSI RISPERIDONE DENGAN LORAZEPAM Kurniati, Tripeni; Darmawan, Endang; Anggriani, Hesti
Jurnal Farmasi Indonesia Vol 10, No 1 (2018)
Publisher : Indonesian Research Gateway

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfi.v10i1.579

Abstract

Treatment with risperidone 1.5-6.0 mg/day provides good benefits for schizophrenia treatment, severe psychiatric disorder with long-term disability potential and limited availability of treatment options. According to the average percentage of patients with abnormal liver function tests, patients with clinically significant improvement (> 3 times of the normal upper limit for SGPT, aspartate aminotransferase.Abnormalities that are commonly without any symptom occur within 6 weeks of antipsychotic use (Correll et al., 2015). The purpose of this study is to analyze the liver function of schizophrenic in-patients who take risperidone and lorazepam in Amino Gondohutomo’s psychiatric hospital of Central of Java Province. The research subjects were 132 schizophrenic diagnosed patients who take risperidone and combination of risperidone and lorazepam. We used Chi Square Tests, Paried T Tests and One Sample Test.Based on the research results, it can be concluded that there is a correlation between readmisi and age group, in age group > 29 years more risk relapse than age group <29 years. Also, it can be concluded the combination of risperidone and lorazepam at risk 0,933 times will increase SGOT than get treatment with risperidone only and therapy the combination of risperidone and lorazepam at risk twice will increase SGPT rather than receive treatment with risperidone only.
AMBARAN FUNGSI HATI PASIEN SKIZOFRENIA YANG MENGKONSUMSI RISPERIDONE DENGAN LORAZEPAM Kurniati, Tripeni; Darmawan, Endang; Anggriani, Hesti
Jurnal Farmasi Indonesia Vol 10, No 1 (2018)
Publisher : Jurnal Farmasi Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1329.822 KB) | DOI: 10.35617/jfi.v10i1.579

Abstract

Treatment with risperidone 1.5-6.0 mg/day provides good benefits for schizophrenia treatment, severe psychiatric disorder with long-term disability potential and limited availability of treatment options. According to the average percentage of patients with abnormal liver function tests, patients with clinically significant improvement (> 3 times of the normal upper limit for SGPT, aspartate aminotransferase.Abnormalities that are commonly without any symptom occur within 6 weeks of antipsychotic use (Correll et al., 2015). The purpose of this study is to analyze the liver function of schizophrenic in-patients who take risperidone and lorazepam in Amino Gondohutomo’s psychiatric hospital of Central of Java Province. The research subjects were 132 schizophrenic diagnosed patients who take risperidone and combination of risperidone and lorazepam. We used Chi Square Tests, Paried T Tests and One Sample Test.Based on the research results, it can be concluded that there is a correlation between readmisi and age group, in age group > 29 years more risk relapse than age group <29 years. Also, it can be concluded the combination of risperidone and lorazepam at risk 0,933 times will increase SGOT than get treatment with risperidone only and therapy the combination of risperidone and lorazepam at risk twice will increase SGPT rather than receive treatment with risperidone only.